Why Jim Cramer's a Fan of GE Selling Its Biopharma Business to Danaher

Here's why Jim Cramer was pleased that General Electric sold its biopharma business to Danaher and what it means for Larry Culp's leadership.
Publish date:

Real Money Stock of the Day General Electric (GE) - Get Report is selling the biopharma portion of its life sciences business to Danaher Corp. (DHR) - Get Report .

Related: General Electric Is Coming Back From the Walking Dead - For Now

GE said the sale won't include its pharmaceutical diagnostics business but expects to use the net proceeds of around $20 billion to reduce its overall debt load. Danaher said the business till operate as as stand-alone company it is own life sciences segment, and will add around 45 cents to 50 cents in adjusted earnings in the first full year after the deal closes.

Jim Cramer thinks that this is a step in the right direction for GE and also believes that it shows CEO Larry Culp's leadership as he navigates GE. 

Over on Cramer's Daily Rundown for Action Alerts Plus, he gave actionable advice for investors and recommended a stock. 

Curious what Cramer recommends? Sign up for Action Alerts Plus here

Watch Jim Cramer's Daily NYSE Show and Replays Below